Jonathan Douros, PhD, is a pharmacologist specializing in incretin therapeutics and metabolic disease. As a scientific advisor at the Indiana Biosciences Research Institute (IBRI), he is dedicated to translating high-impact basic research into early drug discovery projects.
Douros is a native of the Raleigh/Durham region of North Carolina where he attended Shaw University. He went on to perform his doctoral training under Prof. Russell Borski at North Carolina State University studying the role of leptin to regulate metabolic stress responses in the tilapia.
After receiving his PhD in 2015, Douros went on to a postdoctoral fellowship under Dr. David D’Alessio at Duke University assessing the improvements in islet function following bariatric surgery. At Duke, he was able to collaborate with leading incretin biologists and pharmacologists who fostered an appreciation for early drug discovery.
In 2020, Jonathan joined the Novo Nordisk Research Center Indianapolis (NNRCI), where he led in vivo pharmacology efforts with a primary focus in the type 2 diabetes and obesity therapy areas. In 2022, he took the position of associate director of biology and pharmacology leading a team of nine PhD scientists working on drug discovery projects across multiple therapy areas including metabolic and rare diseases.
For a full list of Douros' published research, click here.
Douros lives in Indianapolis with his wife and daughter. Most of his time outside of work is spent with his family and having his cardiovascular function tested by the N.C. State Wolfpack.